Dr. Wang has more than 15 years’ extensive pharmaceutical development experience in nonclinical research and drug development, including early-stage lead compound ADMET screening and late-stage IND and NDA submission; with an emphasis on small molecules and novel drug delivery systems.

Dr. Wang was joined DataRevive in 2019 after serving in the US FDA. He serves as a senior nonclinical consultant helping sponsors design, interpret, troubleshoot, and finalize GLP nonclinical studies to support drug approvals. He also Conducts study reports review, gap-assessment of IND/NDA applications, prepares regulatory submission documentation such as pre-IND briefing packages, INDs and NDAs.

Dr. Wang was a commissioner’s fellow at the office of regulatory affairs of FDA from 2017-2019, where he worked on developing novel LCMS analytical methods for the quality control of liposomal drug products, profiling the lipids oxidation and degradation

products existed in the generic and brand name liposomal drugs for the regulatory purpose.

Prior to that, he was a senior research scientist at NantBiosciences focusing on oncology drug development, including small molecules and antibody-drug conjugates. Dr. Wang also gets trained as a postdoctoral researcher in the department of biochemistry at the University of Texas Southwestern medical center, focusing on an early-stage discovery of tissue regeneration drug candidates. Dr. Wang received his Ph.D. in pharmaceutical sciences from the pharmacy school of Sichuan University in China.